loading page

A predict model to evaluate the level of HBV-DNA for the patients with Chronic Hepatitis B virus (CHB) in clinic: a cross-sectional study
  • +3
  • Jinli Zheng,
  • Juan Wan,
  • Jiang Chenhao,
  • Yang Huang,
  • Xingyu Pu,
  • Li Jiang
Jinli Zheng
Author Profile
Jiang Chenhao
Author Profile
Yang Huang
Author Profile
Li Jiang

Corresponding Author:[email protected]

Author Profile


Background: The previous studies showed the correlation between HBsAg and serum HBV DNA levels were weak or missing. And the relationship of HBeAg and HBV DNA levels was lack. Objective:The study aims to investigate the correlation between HBeAg and HBV DNA levels, and to find an alternative tool to evaluate the HBV DNA levels for clinicians. Methods: We enrolled 1020 patients in this cross-sectional study. We divided the patients into four groups as: HBeAg positivity and negativity groups, high and low HBV DNA levels groups. Further, as to the levels of HBV DNA, we performed subgroups’ in HBeAg-positive and HBeAg-negative groups. Results: The levels of ALT, ALB and HBeAg were the independent factors for the serum HBV DNA in CHB patients. The predict model for the patients with HBeAg-positive was: M1 (high HBV DNA levels) = 1.412 × (1 for HBeAg-positive >16.15 S/CO or 0 for others) + 0.004 × (1 for ALT > 42.5 IU/L or 0 for others) −0.029 × (1 for ALB > 25.5 g/L or 0 for others) + 0.779, and the AUC was 0.606. And the predict model of patients with HBeAg-negative was: M2 (low levels of HBV DNA) = 0.385 − 0.005 × (1 for ALT > 36.5 IU/L or 0 for others) − 0.006 × (1 for TB > 11.15 umol/L or 0 for others), and the AUC was 0.609. Conclusion: HBeAg was an independent risk factor for the patients with HBeAg(+), and when the level of HBeAg was higher than 16.15 S/CO, the patients should have a HBV-DNA test, if not , we should combine with the level of ALT to determine the decision. For the patients with HBeAg(-), we should evaluate the patients to have a HBV-DNA test by the levels of ALT and TB.